0T Whole-Heart Contrast‑Enhanced Coronary Magnetic Resonance Angiography Using Ferumoxytol: A Feasibility Study

This study suggested the feasibility of combining low-dose ferumoxytol (2.0-3.0 mg/kg) with ECG-triggered, navigator-gated, inversion-recovery prepared, segmented gradient-echo sequence to obtain high-quality sub-millimeter 3D whole-heart CMRA images under free-breathing for approximately 7 mins on MR 3.0T scanner. Compared to gadobenate, ferumoxytol produced more intense and prolonged cardiac vessel enhancement (24-36 hours) Ferumoxytol could help to reduce acquisition time of CMRA while maintaining a high signal-to-noise ratio, great image quality, and clear delineation of the coronary arteries. This study of healthy volunteers also suggested that ferumoxytol-enhanced CMRA has the potential to identify patients without coronary artery disease.